In the last years, the management of metastatic colorectal cancer (mCRC) has been relevantly changed by the availability of two classes of biological drugs: the anti-vascular endothelial growth factor (VEGF), bevacizumab (BV) and the anti-epidermal growth factor receptor (EGFR), cetuximab and panitumumab (Labianca et al, 2010). This evidence concerns the gene EGFR and metastatic colorectal cancer.